OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Subscription and Copyright Information	761
Subscription and Copyright Information	490
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	327
Subscription and Copyright Information	199
Advisory Board and Contents	177
Subscription and Copyright Information	177
Subscription and Copyright Information	172
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	160
Peptides as a therapeutic strategy against Klebsiella pneumoniae	151
Muscarinic receptors: from clinic to bench to clinic	144
Shearing of surface mucin saps tumor cell strength	139
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	123
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	117
Structural asymmetry in FGF23 signaling	116
Compstatins: the dawn of clinical C3-targeted complement inhibition	110
Targeting complement in neurodegeneration: challenges, risks, and strategies	104
Structural pharmacology and mechanisms of GLP-1R signaling	104
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	102
Therapeutic inhibition of ferroptosis in neurodegenerative disease	97
Direct in vivo CAR T cell engineering	93
Advisory Board and Contents	90
Advisory Board and Contents	89
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	84
Phenotypic approaches for CNS drugs	83
A smart hospital-driven approach to precision pharmacovigilance	83

Nemolizumab (Nemluvio®) for prurigo nodularis	75
Emerging strategies for beta cell transplantation to treat diabetes	75
HSV-1 as a gene delivery platform for cancer gene therapy	74
Advisory Board and Contents	73
A deep dive into degrader-induced protein-protein interfaces	72
Optogenetic engineering for precision cancer immunotherapy	66
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	65
Leveraging human microbiomes for disease prediction and treatment	64
A perspective on psychedelic teratogenicity: the utility of zebrafish models	64
Ribosome-directed cancer therapies: the tip of the iceberg?	64
Engineering ACE2 decoy receptors to combat viral escapability	63
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	62
Genetically engineered loaded extracellular vesicles for drug delivery	60
siRNA drug Leqvio (inclisiran) to lower cholesterol	60
Advancing non-destructive analysis of 3D printed medicines	59
Suzetrigine for moderate to severe acute pain	59
Advisory Board and Contents	59
The structure, function, and pharmacology of MRGPRs	58
Close to a year in TIPS’ saddle – I am optimistic	57
Subscription and Copyright Information	56
Thriving as members of under-represented groups in pharmacology-related careers	54
Lipoxygenases in chronic liver diseases: current insights and future perspectives	51
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	50
Mentoring future science leaders to thrive	50
Emerging approaches to induce immune tolerance to therapeutic proteins	49
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	49
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	47
Could dexmedetomidine be repurposed as a glymphatic enhancer?	47
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	47
The promise of targeted protein degradation approaches	46
Advisory Board and Contents	46
Piezo1: structural pharmacology and mechanotransduction mechanisms	46
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	42
The road less traveled: activating an oncogenic kinase	42
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	41
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	41
Subscription and Copyright Information	40
Salt-inducible kinases: new players in pulmonary arterial hypertension?	40
Promising neuroimmune targets and drugs for CNS diseases	40
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	40
A novel function of the M2 muscarinic receptor	39
Advisory Board and Contents	39
BTK inhibitors: past, present, and future	38
The end of the beginning in understanding SLC22 polyspecificity	38
Nanocarriers for oral delivery of biologics: small carriers for big payloads	38
Monkeypox: potential vaccine development strategies	37
Frizzleds act as dynamic pharmacological entities	36
Protein acylations in cancer immunity: effects and therapeutic opportunities	36
Validation of agent-based models of surface receptor oligomerisation	35
Decoding pseudouridine: an emerging target for therapeutic development	35

Targeting intracellular protein–protein interactions with macrocyclic peptides	35
Advisory Board and Contents	34
Metabolic regulation in normal and leukemic stem cells	33
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	32
Circulating tumor cells in precision medicine: challenges and opportunities	32
Demographic diversity in platelet function and response to antiplatelet therapy	32
GPR35: from enigma to therapeutic target	32
Eflornithine for treatment of high-risk neuroblastoma	30
Engineered antibody fusion proteins for targeted disease therapy	30
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	30
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	29
Recent advances in generative biology for biotherapeutic discovery	29
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	29
Development of PROTACs using computational approaches	29
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	28
Subscription and Copyright Information	28
Subscription and Copyright Information	28
Tackling chronic kidney disease in diabetic patients with finerenone	27
A novel anticancer pharmacological agent targeting mitochondrial complex I	27
Biochemical perspectives on targeting KMT2 methyltransferases in cancer	27
Intra- and intercellular signaling pathways associated with drug-induced cardiac pathophysiology	27
Subscription and Copyright Information	27
Boosting CAR-T cell therapy through vaccine synergy	26
Targeting plasma membrane cholesterol as a novel anticancer therapy	26
Targeting sensory neuron GPCRs for peripheral neuropathic pain	26
Harnessing associative learning paradigms to optimize drug treatment	26
High-power screening (HPS) empowered by DNA-encoded libraries	25
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	25
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	25
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	25
Biologics and cardiac disease: challenges and opportunities	25
Subscription and Copyright Information	24
Neutrophil extracellular traps in wound healing	24
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	24
Visceral obesity and HFpEF: targets and therapeutic opportunities	24
Recent advancements in vaccine research and development	24
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	24
Teaching an old dog new tricks: repurposing β-lactams	23
Taming PRMT5–adaptor protein interactions	23
Challenges and opportunities associated with rare-variant pharmacogenomics	23
Circadian biology to advance therapeutics for mood disorders	22
GABAA receptors as targets for treating affective and cognitive symptoms of depression	22
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	22
NLRP3 and pyroptosis blockers for treating inflammatory diseases	21
Potential for targeting small heat shock protein modifications	21
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	21
Advisory Board and Contents	21
GPCR-dependent and -independent arrestin signaling	20
Odorant receptors as potential drug targets	20
Glymphatic-stagnated edema induced by traumatic brain injury	20
Subscription and Copyright Information	20
Targeted protein degrader development for cancer: advances, challenges, and opportunities	19
The structure and function of YTHDF epitranscriptomic m6A readers	19
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	19
Membrane protein production and formulation for drug discovery	19
Structural perspective of class B1 GPCR signaling	18
Advisory Board and Contents	18
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	18
Hans Jürg Schatzmann (1924–2021)	18
Bridging the gap in neuropsychiatric translational research	18
Advisory Board and Contents	18